Compassionate Use of Pirtobrutinib for a Patient with Waldenstrom s macroglobulinemia.

Go Back to All Clinical Trials

Compassionate Use of Pirtobrutinib for a Patient with Waldenstrom s macroglobulinemia.

Brief description of study

You can participate in this study if you are diagnosed with Waldenstrom’s macroglobulinemia. In this study we will evaluate the study drug (Pirtobrutinib) for the treatment of Waldenstrom’s macroglobulinemia.

The purpose of this study is to determine the efficacy, safety and tolerability of the study drug (Pirtobrutinib). The study is also being done to learn more about how the study drug is absorbed (taken up in the body), metabolized (broken-down by the body), distributed (circulated in the body), and eliminated (passed out of the body). The patients will be monitored and taken care of while on this medication during the entire study period.

Clinical Study Identifier: s22-00990

ClinicalTrials.gov Identifier: NCT05172700

Principal Investigator: Michael L. Grossbard.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies